Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc Issues FY 2013 Guidance; Revenue And Net Income Guidance Below Analysts' Estimates


Thursday, 21 Feb 2013 04:03pm EST 

Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects total revenue of $530 to $555 million, GAAP net loss of $(195) to $(170) million and non-GAAP adjusted EBITDA (loss) $(75) to $(50) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $563 million, net income of ($115) million and EBITDA of ($68) million for fiscal 2013. 

Related Company News

Company Quote

81.03
6.02 +8.03%
24 Oct 2014